BR112022004376A2 - Ativação de piruvato quinase r - Google Patents

Ativação de piruvato quinase r

Info

Publication number
BR112022004376A2
BR112022004376A2 BR112022004376A BR112022004376A BR112022004376A2 BR 112022004376 A2 BR112022004376 A2 BR 112022004376A2 BR 112022004376 A BR112022004376 A BR 112022004376A BR 112022004376 A BR112022004376 A BR 112022004376A BR 112022004376 A2 BR112022004376 A2 BR 112022004376A2
Authority
BR
Brazil
Prior art keywords
activation
pyruvate kinase
compositions
dioxino
tetrahydropyrrolo
Prior art date
Application number
BR112022004376A
Other languages
English (en)
Inventor
Anna Ericsson
R Jr Lancia David
David Richard
Gary Gustafson
Gary Marshall
Lorna Mitchell
Madhu Mondal
Maria Ribadeneira
Neal Green
Patricia Schroeder
F Kelly Patrick
Sanjeev Forsyth
Zhongguo Wang
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/576,360 external-priority patent/US10675274B2/en
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of BR112022004376A2 publication Critical patent/BR112022004376A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ativação de piruvato quinase r. a presente invenção refere-se a composto (s)-1-(5-((2,3-di-hidro-[1,4]dioxino[2,3-b]piridin-7-il)sulfonil)-3,4,5,6-tetra-hidropirrolo[3,4-c]pirrol-2(1h)-il)-3-hidróxi-2-fenilpropan-1-ona ou um sal farmaceuticamente aceitável do mesmo, que é útil para aumentar a afinidade de hemoglobina para oxigênio. métodos e composições para o tratamento de hemoglobinopatias que incluem certas composições farmacêuticas para ativar pkr são fornecidos no presente documento.
BR112022004376A 2019-09-19 2020-09-18 Ativação de piruvato quinase r BR112022004376A2 (pt)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962902887P 2019-09-19 2019-09-19
US16/576,360 US10675274B2 (en) 2018-09-19 2019-09-19 Activating pyruvate kinase R
PCT/US2019/052024 WO2020061378A1 (en) 2018-09-19 2019-09-19 Treating sickle cell disease with a pyruvate kinase r activating compound
US16/576,720 US20200129485A1 (en) 2018-09-19 2019-09-19 Treating sickle cell disease with a pyruvate kinase r activating compound
US201962906437P 2019-09-26 2019-09-26
US202063024432P 2020-05-13 2020-05-13
US202063024441P 2020-05-13 2020-05-13
US202062704785P 2020-05-28 2020-05-28
US202062705106P 2020-06-11 2020-06-11
PCT/US2020/051579 WO2021055807A1 (en) 2019-09-19 2020-09-18 Activating pyruvate kinase r

Publications (1)

Publication Number Publication Date
BR112022004376A2 true BR112022004376A2 (pt) 2022-06-07

Family

ID=74884722

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022004376A BR112022004376A2 (pt) 2019-09-19 2020-09-18 Ativação de piruvato quinase r
BR112022004715A BR112022004715A2 (pt) 2019-09-19 2020-09-18 Composições de ativação de piruvato quinase r (pkr)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022004715A BR112022004715A2 (pt) 2019-09-19 2020-09-18 Composições de ativação de piruvato quinase r (pkr)

Country Status (9)

Country Link
US (2) US20220378755A1 (pt)
EP (2) EP4031132A4 (pt)
KR (2) KR20220066272A (pt)
CN (2) CN114615977A (pt)
AU (2) AU2020349555A1 (pt)
BR (2) BR112022004376A2 (pt)
CA (2) CA3151610A1 (pt)
MX (2) MX2022003254A (pt)
WO (1) WO2021055807A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ763766A (en) 2017-03-20 2023-07-28 Novo Nordisk Healthcare Ag Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237530A (zh) * 2009-04-03 2016-01-13 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途
BR122020010643B1 (pt) * 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
US20170216434A1 (en) * 2014-08-05 2017-08-03 Wayne State University Compositions and methods for treatment of sickle cell disease
JP6453482B2 (ja) * 2015-03-10 2019-01-16 シオノギ インク． 固体分散体
NZ763766A (en) * 2017-03-20 2023-07-28 Novo Nordisk Healthcare Ag Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
CN110193012B (zh) * 2018-02-27 2022-02-08 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法
BR112021005188A2 (pt) * 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r

Also Published As

Publication number Publication date
MX2022003025A (es) 2022-04-07
KR20220066272A (ko) 2022-05-24
EP4031132A1 (en) 2022-07-27
BR112022004715A2 (pt) 2022-06-14
KR20220066058A (ko) 2022-05-23
WO2021055807A1 (en) 2021-03-25
US20220378756A1 (en) 2022-12-01
MX2022003254A (es) 2022-04-18
EP4031133A1 (en) 2022-07-27
CN114615977A (zh) 2022-06-10
CA3151610A1 (en) 2021-03-25
EP4031132A4 (en) 2023-09-13
CA3151612A1 (en) 2021-03-25
AU2020349555A1 (en) 2022-04-07
CN114650817A (zh) 2022-06-21
AU2020350763A1 (en) 2022-04-07
EP4031133A4 (en) 2023-12-27
US20220378755A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
BR112022004376A2 (pt) Ativação de piruvato quinase r
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
WO2018155916A3 (ko) 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
PT1121363E (pt) Pirazole[3,4-d]pirimidin-4-onas substituidas na posicao 6, uteis como inibidores de cinase dependentes de ciclina
GB201104267D0 (en) Pyrrolopyridineamino derivatives
TW200614990A (en) Methods for preparing indazole compounds
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
WO2006124863A3 (en) Pyrrolopyridine derivatives as protein kinase inhibitors
MX2021001096A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
CL2007001554A1 (es) Compuestos derivados de pirido [3,2-e]pirazinas;inhibidoras de pde10;procedimiento de preparacion;composicion farmaceutica que comprende; kit farmaceutico; uso para preparar de un medicamento para tratar o prevenir trastornos asociados a la hiperactividad de pde10 y/o trastornos en los que inhibir la pde10 es de valor.
RS51123B (sr) Aril fuzionisana azapoliciklična jedinjenja
TN2019000332A1 (en) Methods of treating pediatric cancers
MX2020009586A (es) Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk.
IL184064A0 (en) TRICYCLIC ?ì-OPIOID MODULATORS
MA34844B1 (fr) Derives de (1,2,4) triazolo[4,3-a]quinoxaline comme inhibiteurs de phosphodiestérases
WO2005023807A3 (en) 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
WO2018038988A3 (en) Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
MX2021002051A (es) Imidazo[1,2-b]piridaziinas como inhibidores de trk.
MX2019013198A (es) Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9).
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
MX2024008057A (es) Compuestos de pirazina como inhibidores de flt3.
MX2019012758A (es) Regimen terapeutico de 2-amino-1-(2-(4-fluorofenil)-3-(4-fluorofen ilamino)-8,8-dimetil-5,6-dihidroimidazo [1,2-a]pirazin-7(8h)-il)et anona y combinaciones de la misma.
MX2022005976A (es) Compuestos antagonistas de receptores de adenosina.
MX2021000683A (es) Derivados de imidazo[1,2-b]piridazina como inhibidores de trk.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]